- Click to view Current Clinical Trials
- ASSET (Abatacept Systemic SclErosis Trial) is an international, placebo-controlled, double blind, randomized trial of early diffuse cutaneous systemic sclerosis (SSc). This trial assesses abatacept (Orencia®, a recombinant fusion protein consisting of the extracellular domain of human CTLA4 is FDA approved biologic medication for rheumatoid arthritis and juvenile arthritis) in patients with early diffuse SSc with less than or equal to 36 months. The primary outcomes are to assess improvement in skin thickness and safety. The trial is a 12 month double blind study and is followed by a 6 month open label extension. Secondary and exploratory outcomes will include changes in the patient-reported outcomes, pulmonary function tests, joint swelling and tenderness, and other laboratory measures. See ASSET website.
- Pilot study to assess the efficacy and safety of riociguat vs. placebo in scleroderma–associated digital ulcers
Do you have Scleroderma?
Have you suffered from ulcers or sores on your fingertips?
Do you currently have an ulcer or sore that has opened within the last 8 weeks?
- We are currently conducting a trial of riociguat (Adempas®) vs. placebo in scleroderma-associated digital ulcers.
- Riociguat is approved by the FDA in the US for another indication: pulmonary hypertension.
- There is a 50/50 chance of receiving either the study drug: riociguat or placebo (which contains no active ingredients). This portion of the study will continue for 16 weeks.
- After completing the 16 weeks on riociguat/ placebo, the participant may have the opportunity to continue in the study for an additional 16 weeks during which they will receive the study medication: riociguat.
- The study drug and associated assessments are of no cost to the participant.
- Patient stipend is included and if traveling from some distance associated travel costs can be covered for the participant by the study.
For more information, contact:
Aaron Rankin: firstname.lastname@example.org / 734-763-4866
Erica Bush: email@example.com / 734-936-5615
Click here to view the poster for this study.
to Research - Top